May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Vitreous Levels of VEGF and SDF-1 in Patients with Diabetic Retinopathy
Author Affiliations & Notes
  • H.L. Brooks
    Southern Vitreoretinal Assoc PA, Tallahassee, FL, United States
  • C.K. Newell
    Southern Vitreoretinal Assoc PA, Tallahassee, FL, United States
  • R.L. Steinmetz
    Southern Vitreoretinal Assoc PA, Tallahassee, FL, United States
  • J. Fortin
    Southern Vitreoretinal Assoc PA, Tallahassee, FL, United States
  • S. Caballero
    Pharmacology/Therapeutics, University of Florida, Gainesville, FL, United States
  • M.B. Grant
    Pharmacology/Therapeutics, University of Florida, Gainesville, FL, United States
  • Footnotes
    Commercial Relationships  H.L. Brooks, None; C.K. Newell, None; R.L. Steinmetz, None; J. Fortin, None; S. Caballero, None; M.B. Grant, None.
  • Footnotes
    Support  EY012601 and EY007739
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4285. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.L. Brooks, C.K. Newell, R.L. Steinmetz, J. Fortin, S. Caballero, M.B. Grant; Vitreous Levels of VEGF and SDF-1 in Patients with Diabetic Retinopathy . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4285.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Proliferative diabetic retinopathy (PDR), the leading cause of adult blindness, is characterized by aberrant neovascularization (NV). Endothelial cell precursors circulate in the bloodstream, are recruited to sites of neoangiogenesis and participate in new blood vessel formation. These precursors express the chemokine receptor CXCR4 and migrate in response to stromal derived factor (SDF-1), a highly conserved member of the CXC chemokine family. SDF-1 is a potent stimulator of vascular endothelial growth factor (VEGF) expression, the main effector of retinal NV. We proposed to investigate the relationship between SDF-1 and VEGF in the vitreous fluid of diabetic patients with varying degrees of diabetic retinopathy and cystoid macular edema (CME) before and after intraocular injection of Triamcinolone. Methods: In this prospective study, 40 patients were included. 27 eyes were classified as nonproliferative diabetic retinopathy (NPDR), 11 eyes were classified as inactive proliferative diabetic retinopathy (PDR) with CME, 12 eyes with mild PDR with or without CME, 20 eyes with florid PDR with or without CME, and 9 eyes with neovascular glaucoma (NVG) or NV of the iris (NVI). Vitreous (0.5-0.6 ml) was obtained prior to injection of Triamcinolone 4 mg. VEGF and SDF-1 were measured by ELISA. Results: Vitreous levels of both VEGF and SDF-1 were significantly higher (p<0.01) in diabetic patients with PDR (VEGF: 303-2,722 ng/ml; SDF-1: 120-300 pg/ml) than in patients with NPDR (VEGF: 235±47.3 ng/ml; SDF-1: 95±29.7 pg/ml). SDF-1 levels were markedly increased in patients with CME (70±18.7 pg/ml) compared to those without (35±13.6 pg/ml). Triamcinolone administration resulted in the dramatic reduction of VEGF and SDF-1 to nearly undetectable levels. Triamcinolone eliminated CME, NVI and caused regression of active NV and the initiation of fibrosis. Conclusions: Elevated SDF-1 is associated with the presence of CME and is reduced by Triamcinolone. The elimination of CME and NVI, as well as the regression of active neovascularization and the initiation of fibrosis by Triamcinolone may be due to the suppression of VEGF and SDF-1. Our results support a role for SDF-1 and VEGF in the pathogenesis of diabetic retinopathy.

Keywords: diabetic retinopathy • neovascularization • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×